DdATP (lithium)

• Description:

  DdATP (lithium) (2',3'-Dideoxyadenosine 5'-triphosphate (lithium) ) is an active metabolite of 2',3'-dideoxyinosine and a DNA polymerase chain elongation inhibitor. ddATP (lithium) is used in Sanger DNA sequencing and in research related to viral infection[1][2][3][4][5].

• Product Name Alternative:

  2',3'-Dideoxyadenosine 5'-triphosphate (lithium)

• UNSPSC:

  12352005

• Target:

  DNA/RNA Synthesis; HIV

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Field of Research:

  Infection

• Smiles:

  NC1=NC=NC2=C1N=CN2[C@H]3CC[C@H] (O3) COP (O) (OP (OP (O) (O[Li]) =O) (O) =O) =O

• Molecular Formula:

  C10H15LiN5O11P3

• Molecular Weight:

  481.12

• References & Citations:

  [1]van der Vliet PC, et al. Role of DNA polymerase gamma in adenovirus DNA replication. Mechanism of inhibition by 2',3'-dideoxynucleoside 5'-triphosphates. Biochemistry. 1981 Apr 28;20 (9) :2628-32.|[2]Xu Lan, et al. Simultaneous determination of 2 ,3 -dideoxyinosine and the active metabolite, 2 ,3 -dideoxyadenosine-5 -triphosphate in human peripheral-blood mononuclear cell by HPLC–MS/MS and the application to cell pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:337-42.|[3]Jun-Yu Ma, et al. Double-strand breaks induce short-scale DNA replication and damage amplification in the fully grown mouse oocytes. Genetics. 2021 Jun 24;218 (2) :iyab054.|[4]C M Perry, et al. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs. 1996 Dec;52 (6) :928-62.|[5]Hao Z, et al. Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol. 1988 Oct;34 (4) :431-5.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported